A5020794811- Cardiac Arrhythmias and Treatments
- Atrial Fibrillation Management and Outcomes
- Cardiac pacing and defibrillation studies
- Cardiac electrophysiology and arrhythmias
- ECG Monitoring and Analysis
- Blood Pressure and Hypertension Studies
- Cardiovascular Syncope and Autonomic Disorders
- Cardiac Imaging and Diagnostics
- Heart Rate Variability and Autonomic Control
- Cardiac Structural Anomalies and Repair
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiovascular Function and Risk Factors
- Neurological disorders and treatments
- Cardiac Health and Mental Health
- Cardiovascular Effects of Exercise
- Cardiomyopathy and Myosin Studies
- Cardiac Valve Diseases and Treatments
- Acute Myocardial Infarction Research
- Cardiac Arrest and Resuscitation
- Health Systems, Economic Evaluations, Quality of Life
- Ion channel regulation and function
- Phonocardiography and Auscultation Techniques
- Venous Thromboembolism Diagnosis and Management
- Cardiac tumors and thrombi
- Botulinum Toxin and Related Neurological Disorders
University of Rochester
2015-2024
University of Rochester Medical Center
2011-2023
Summit Medical Group (United States)
2016-2023
Center for Discovery
2020-2023
BayCare Health System
2023
Stroke Association
2022
Valley Health System
2012-2021
The Arrhythmia Institute
2012-2020
Hackensack Meridian Health
2020
Seton Hall University
2019
Background— In 1994, an International Task Force proposed criteria for the clinical diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) that facilitated recognition and interpretation frequently nonspecific features ARVC/D. This enabled confirmatory in index cases through exclusion phenocopies provided a standard on which research genetic studies could be based. Structural, histological, electrocardiographic, arrhythmic, familial disease were incorporated into...
In 1994, an International Task Force proposed criteria for the clinical diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) that facilitated recognition and interpretation frequently nonspecific features ARVC/D. This enabled confirmatory in index cases through exclusion phenocopies provided a standard on which research genetic studies could be based. Structural, histological, electrocardiographic, arrhythmic, familial disease were incorporated into criteria,...
Background — Implantable cardioverter defibrillator (ICD) use reduces mortality in patients with serious ventricular arrhythmias compared antiarrhythmic drug (AAD) use. However, the relative impact of these therapies on self-perceived quality life (QoL) is unknown. Methods and Results Three self-administered instruments were used to measure generic disease-specific QoL Antiarrhythmics Versus Defibrillators trial participants. Generalized linear models assess relationships between treatment...
Introduction: This study was designed to assess whether right ventricular pacing in the implantable cardioverter defibrillator (ICD) arm of Multicenter Automatic Defibrillator Implantation Trial (MADIT) II associated with an unfavorable outcome. Methods and Results: Data on number paced beats were available 567 (76%) 742 MADIT patients ICDs. The over total showed a bimodal distribution being predominantly or nonpaced. Therefore, dichotomized at 0–50% 51–100% cumulative median rate 0.2%...
Background— We hypothesized that combined assessment of factors are associated with favorable reverse remodeling after cardiac resynchronization-defibrillator therapy (CRT-D) can be used to predict clinical response the device. Methods and Results— The study population comprised 1761 patients enrolled in Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT). Best-subset regression analysis was performed identify echocardiographic (defined...
<h3>Importance</h3> Renal denervation can reduce cardiac sympathetic activity that may result in an antiarrhythmic effect on atrial fibrillation. <h3>Objective</h3> To determine whether renal when added to pulmonary vein isolation enhances long-term efficacy. <h3>Design, Setting, and Participants</h3> The Evaluate Denervation Addition Catheter Ablation Eliminate Atrial Fibrillation (ERADICATE-AF) trial was investigator-initiated, multicenter, single-blind, randomized clinical conducted at 5...
Atrial fibrillation (AF) is a commonly encountered arrhythmia in clinical practice, and it occurs frequently after cardiac surgery. The P-wave signal-averaged (SA) ECG noninvasively detects atrial conduction delay. Prior studies have described greater prolongation patients with history of AF, but prospective not been performed.Consecutive undergoing surgery were enrolled. SAECG was recorded before from three orthogonal leads using sinus template cross-correlation function. averaged P wave...
Expectations that reestablishing and maintaining sinus rhythm in patients with atrial fibrillation might improve survival were disproved the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. This report describes cause-specific modes death AFFIRM treatment groups.All deaths enrolled underwent blinded review by Events Committee, a mode was assigned. In AFFIRM, 2033 randomized to rhythm-control strategy 2027 rate-control strategy. During mean follow-up 3.5 years,...
Cardiac resynchronization therapy (CRT) alone or combined with an implantable defibrillator (CRT-D) has been shown to improve exercise capacity and quality of life reduce heart failure (HF) hospitalizations mortality in patients New York Heart Association (NYHA) class III IV HF. There is concern that the device procedure may destabilize these very ill patients. We sought examine outcomes NYHA enrolled Comparison Medical Therapy, Pacing, Defibrillation Failure (COMPANION) trial assess...
Despite encouraging results of pulmonary vein isolation (PVI) ablation for atrial fibrillation (AF), it is unclear whether there genuine cure or an important attrition rate. We sought to determine the long-term outcome initial responders who experienced a prolonged AF-free complete response.From series 350 consecutive patients underwent PVI AF, 264 (75%) (males 71%, age 57 +/- 12 years, paroxysmal AF 87%) demonstrated >or=1 year follow-up on no antiarrhythmic drugs were followed 1-5...
We are in the midst of a rapidly evolving era technology-assisted medicine. The field telemedicine provides opportunity for highly individualized medical management way that has never been possible before. Evolving technologies using cardiac implantable devices (CIEDs) with capabilities remote monitoring permit evaluation multiple parameters cardiovascular physiology and risk, including rhythm, device function, blood pressure values, presence myocardial ischaemia, degree compensation...
In the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial, 1520 patients with advanced heart failure were assigned a 1:2:2 ratio to optimal pharmacological therapy or plus cardiac resynchronization (CRT-P) CRT defibrillator (CRT-D). Use CRT-P CRT-D was associated significant reduction combined risk death all-cause hospitalizations. Because mortality also significantly reduced (optimal versus only), an assessment true hospitalization rates must...
The success of pulmonary vein isolation (PVI) for atrial fibrillation (AF) may be improved if stable AF sources identified by Focal Impulse and Rotor Mapping (FIRM) are also eliminated. long-term results this approach unclear outside the centers where FIRM was developed; thus, we assessed outcomes FIRM-guided ablation in first cases at 10 experienced centers.